155 related articles for article (PubMed ID: 15825161)
1. The efficacy of epirubicin, cisplatin, uracil/tegafur, and leucovorin in patients with advanced biliary tract carcinoma.
Park KH; Choi IK; Kim SJ; Oh SC; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
Cancer; 2005 Jun; 103(11):2338-43. PubMed ID: 15825161
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma.
Jeen YT; Yoon SY; Shin SW; Kim BS; Mok YJ; Kim CS; Hyun JH; Kim JS; Kim YH
Cancer; 2001 Jun; 91(12):2288-93. PubMed ID: 11413517
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of cisplatin, epirubicin, UFT, and leucovorin (PELUF) as first-line chemotherapy in metastatic gastric cancer.
Idelevich E; Karminsky N; Dinerman M; Katsenelson RL; Zvi NB; Baruch NB; Biran H; Man S; Shani A
Acta Oncol; 2007; 46(3):324-9. PubMed ID: 17450467
[TBL] [Abstract][Full Text] [Related]
4. Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer.
Furuse J; Okusaka T; Funakoshi A; Yamao K; Nagase M; Ishii H; Nakachi K; Ueno H; Ikeda M; Morizane C; Horikawa Y; Mizuno N
Jpn J Clin Oncol; 2006 Sep; 36(9):552-6. PubMed ID: 16887837
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of epirubicin, cisplatin and uracil-tegafur for advanced gastric carcinoma.
Woo IS; Moon DH; Shim BY; Lee MA; Byun JH; Kim KW; Kang JH; Choi MG; Chung IS; Hong YS; Park SY; Lee KS
Jpn J Clin Oncol; 2005 Jan; 35(1):13-7. PubMed ID: 15681598
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
Furuse J; Okusaka T; Ohkawa S; Nagase M; Funakoshi A; Boku N; Yamao K; Yamaguchi T; Sato T
Cancer Chemother Pharmacol; 2009 Dec; 65(1):113-20. PubMed ID: 19404641
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors.
Cantore M; Mambrini A; Fiorentini G; Rabbi C; Zamagni D; Caudana R; Pennucci C; Sanguinetti F; Lombardi M; Nicoli N
Cancer; 2005 Apr; 103(7):1402-7. PubMed ID: 15726542
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and toxicity of lower dose UFT without leucovorin in metastatic gastric cancer patients.
Somali I; Meydan N; Tarhan MO; Oztop I; Alacacioglu A; Yilmaz U
J BUON; 2009; 14(3):429-33. PubMed ID: 19810134
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of Uracil-tegafur (UFT) in patients with advanced biliary tract carcinoma.
Ikeda M; Okusaka T; Ueno H; Morizane C; Furuse J; Ishii H
Jpn J Clin Oncol; 2005 Aug; 35(8):439-43. PubMed ID: 16024530
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of oxaliplatin combined with leucovorin and fluorouracil for recurrent/metastatic biliary tract carcinoma.
Lim JY; Jeung HC; Mun HS; Lee DK; Paik YH; Lee SJ; Yoon DS; Cho JY
Anticancer Drugs; 2008 Jul; 19(6):631-5. PubMed ID: 18525323
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin, tegafur, and leucovorin: a moderately effective and minimally toxic outpatient neoadjuvant chemotherapy for locally advanced squamous cell carcinoma of the head and neck.
Wang HM; Wang CS; Chen JS; Chen IH; Liao CT; Chang TC
Cancer; 2002 Jun; 94(11):2989-95. PubMed ID: 12115388
[TBL] [Abstract][Full Text] [Related]
12. Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma.
Kim SJ; Seo HY; Choi JG; Sul HR; Sung HJ; Park KH; Choi IK; Oh SC; Yoon SY; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
Cancer Chemother Pharmacol; 2006 Apr; 57(4):436-42. PubMed ID: 16049620
[TBL] [Abstract][Full Text] [Related]
13. A multiple-center phase II study of biweekly oxaliplatin and tegafur-uracil/leucovorin for chemonaive patients with advanced gastric cancer.
Chen JS; Rau KM; Chen YY; Huang JS; Yang TS; Lin YC; Liau CT; Lee KD; Su YC; Kao RH
Cancer Chemother Pharmacol; 2009 Apr; 63(5):819-25. PubMed ID: 18663448
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study.
Chang PM; Chen PM; Chu PY; Wang LW; Tai SK; Tsai TL; Huang JL; Wang YF; Chang SY; Yang MH
Cancer Chemother Pharmacol; 2008 Dec; 63(1):9-17. PubMed ID: 18343925
[TBL] [Abstract][Full Text] [Related]
15. Epirubicin, cisplatin, oral UFT, and calcium folinate in advanced gastric carcinoma.
Kim YH; Kim BS; Seo JH; Choi CW; Kim JS; Chun HJ; Hyun JH; Kim JS
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):64-8. PubMed ID: 10442365
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of uracil-tegafur plus cisplatin in patients with previously untreated advanced non-small cell lung cancer.
Takayama K; Kawasaki M; Ninomiya K; Motohiro A; Fujita M; Watanabe K; Kajiki A; Iwami F; Miyazaki N; Izumi M; Hara N; Nakanishi Y;
Respirology; 2008 Jan; 13(1):103-7. PubMed ID: 18197918
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of Orzel (UFT plus leucovorin), cisplatin, and radiotherapy in the treatment of potentially resectable esophageal cancer.
Tedesco KL; Berlin J; Blanke CD; Teng M; Choy H; Roberts J; Beauchamp RD; Leach S; Wyman K; Tarpley J; Shyr Y; Caillouette C; Chakravarthy B
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1364-70. PubMed ID: 15817338
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.
Shirao K; Hoff PM; Ohtsu A; Loehrer PJ; Hyodo I; Wadler S; Wadleigh RG; O'Dwyer PJ; Muro K; Yamada Y; Boku N; Nagashima F; Abbruzzese JL
J Clin Oncol; 2004 Sep; 22(17):3466-74. PubMed ID: 15277535
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of UFT/leucovorin, carboplatin, and paclitaxel in combination with external beam radiation therapy for advanced esophageal carcinoma.
Czito BG; Cohen DP; Kelsey CR; Lockhart AC; Bendell JC; Willett CG; Petros WP; D'Amico TA; Truax R; Hurwitz HI
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1066-72. PubMed ID: 17881149
[TBL] [Abstract][Full Text] [Related]
20. Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer.
Rao S; Cunningham D; Hawkins RE; Hill ME; Smith D; Daniel F; Ross PJ; Oates J; Norman AR
Br J Cancer; 2005 May; 92(9):1650-4. PubMed ID: 15856037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
